2023-04-28 16:00Financial Performance - Operating revenue fell by 79.86% due to a significant decrease in demand for COVID-19 vaccines compared to last year[14] - Net profit attributable to shareholders decreased by 214.94%, leading to a loss for the company[14] - Basic and diluted earnings per share were both -0.57 RMB, compared to 0.49 RMB in the previous year[22] - The company reported a net loss of -170,199, compared to a profit of 114,295 in the same period last year, marking a significant shift in performance[33] - Total operating revenue for Q1 2023 was CNY 100,553 thousand, a decrease of 79.86% compared to CNY 499,355 thousand in Q1 2022[55] - Net profit attributable to shareholders for Q1 2023 was CNY -139,547 thousand, representing a decline of 214.94% year-over-year[60] - Basic and diluted earnings per share for Q1 2023 were both CNY -0.57, a decrease of 216.33% compared to the previous year[60] Assets and Liabilities - Total assets decreased by 2.21% to RMB 11,215,389,000 compared to the previous year[13] - The total non-current assets increased to RMB 3,894,808,000, up from RMB 3,738,775,000[7] - The total assets amounted to 7,320,581, a decrease from 7,730,185, indicating a 5.3% decline[30] - The total liabilities as of Q1 2023 were CNY 4,137,354 thousand, a slight decrease from CNY 4,223,358 thousand in the previous year[54] - The company's total equity decreased to CNY 7,078,035 thousand from CNY 7,245,602 thousand year-over-year[54] - The total equity attributable to shareholders decreased by 2.03% to RMB 6,611,175,000[13] Cash Flow - The company reported a net cash flow from operating activities that was not applicable due to a decrease in cash paid for raw material procurement[14] - The net cash flow from operating activities was -345,404, a decrease from -598,148 in the previous year, indicating a 42.3% improvement[24] - Cash inflow from operating activities totaled CNY 140,298 thousand, compared to CNY 230,369 thousand in the same period last year[49] - Cash and cash equivalents at the end of the period stood at 2,843,894, down from 3,973,871, reflecting a 28.5% decrease[25] - Cash inflow from financing activities was 409,925, down from 517,416, reflecting a 20.8% decrease[24] Research and Development - R&D investment totaled RMB 150,871,000, representing an increase of 118.12 percentage points in R&D expenditure as a percentage of operating income[12] - Research and development expenses accounted for 118.12 percentage points increase in proportion to operating income, due to a larger decline in operating income compared to R&D expenses[49] Shareholder Information - The number of common shareholders at the end of the reporting period was 23,808[4] - The company has a total of 98,066,497 shares held by HKSCC NOMINEES LIMITED, accounting for 39.63% of total shares[4] - The accumulated undistributed profits reached -215,229,160.88, with total share capital at 247,449,899, indicating that the undistributed losses exceed one-third of the paid-in capital[29] Investment Activities - Total cash inflow from investing activities was 2,787,236, up from 2,135,294, representing a 30.6% increase[24] - The net cash flow from investing activities was -172,009, an improvement from -894,010, showing a 80.7% reduction in losses[24] Foreign Exchange - The company experienced a foreign exchange loss of -19,486, compared to -12,150 in the previous year, indicating increased volatility in currency impacts[24] Future Plans - The company plans to issue Global Depository Receipts (GDR) to enhance international financing channels and brand image[28]